IPP Bureau
Fluor to provide EPCM services for pharmaceutical facility in Indiana
By IPP Bureau - April 07, 2025
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
By IPP Bureau - April 07, 2025
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Lupin acquires UK-based Renascience Pharma for £12.3 million
By IPP Bureau - April 04, 2025
The portfolio includes branded injectable cephalosporines for infectious diseases
Gland Pharma receives approval for Acetaminophen Injection
By IPP Bureau - April 04, 2025
The company expects to launch this product through its marketing partner in the near future
Sai Life Sciences sets up Peptide Research Center in India
By IPP Bureau - April 04, 2025
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
SPARC announces submission of IND Application for SBO-154 to USFDA
By IPP Bureau - April 04, 2025
The IND application supports the next phase of development of SBO-154
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
By IPP Bureau - April 04, 2025
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
By IPP Bureau - April 04, 2025
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
By IPP Bureau - April 04, 2025
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Enhertu approved in EU in post-ET breast cancer
By IPP Bureau - April 04, 2025
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025
By IPP Bureau - April 04, 2025
Awards highlight Avantor's commitment to the Biopharma industry
Naturo & Orgo empowering brands through excellence
By IPP Bureau - April 03, 2025
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Knya forays into medical equipment category with '6sense Stethoscope'
By IPP Bureau - April 03, 2025
The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings
Alembic announces USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial
By IPP Bureau - April 03, 2025
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
